AbCellera Biologics Inc. AbCellera Biologics Inc.

AbCellera Biologics Inc.

ABCL

Rangering i aksjer #4146
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Aksjekurs
$12.04
Markedsverdi
$3.90B
Endring (1 dag)
2.03%
Endring (1 år)
115.38%
Land
CA
Handel AbCellera Biologics Inc. (ABCL)

Kategori

Healthcare
Utbyttehistorikk for AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (aksjesymbol: ABCL) har gitt totalt 0 utbyttebetalinger.
Summen av alle utbytter (justert for aksjesplitt): 0.00
Utbytteavkastning (TTM): 0
Utbyttebetalinger for AbCellera Biologics Inc. (ABCL) fra 2026 til 2026
Årlige utbyttebetalinger
År Utbytte (justert for aksjesplitt) Endre
Ikke nok data for de angitte datoene.
Liste over alle utbyttebetalinger
År Utbytte Endre
Ikke nok data for de angitte datoene.
Utbyttebetalinger for lignende selskaper eller konkurrenter
Selskap Antall utbyttebetalinger Land
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL